logo
The Cost Breztri of with Medicare

The Cost Breztri of with Medicare

Health Line13 hours ago

Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan.
Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) is a metered-dose inhaler designed for adults living with chronic obstructive pulmonary disease (COPD).
Medicare might help cover the cost of Breztri for COPD, but it's important to check the specifics of your plan, as there's no nationwide rule for inhaler coverage. Each Medicare Part D or Medicare Advantage Prescription Drug (MAPD) plan may cover different drugs.
However, note that if you need a nebulizer rather than an inhaler, you would typically be covered under Medicare Part B.
How much does Breztri cost with Medicare?
If you don't have insurance, a 5.9-gram (g) Breztri inhaler costs around $400, while a larger 10.7-g inhaler can cost about $700.
Whether your Medicare drug plan covers a Breztri inhaler depends on its formulary, which is a list of covered medications that varies with each plan. If your plan's formulary doesn't include this inhaler, it might offer coverage for a different one instead.
If your plan covers Breztri, the amount you need to pay depends on its tier within the formulary. Higher tiers usually mean a higher cost. However, starting in 2025, you'll pay no more than $2,000 annually out of pocket for drugs through Medicare plans.
Remember, Part D and MAPD plans are managed by private insurance companies, meaning your deductibles, premiums, and copays will depend on your plan. In 2025, the national base beneficiary premium for Part D is $36.78, and according to the Centers for Medicare & Medicaid Services (CMS), the average monthly premium for Medicare Advantage plans is about $17.
If you use a nebulizer and have coverage under Part B, you'll pay 20% of the cost after meeting your annual deductible of $257, as long as you keep up with your monthly premium of $185.
How can I get cheaper Breztri with Medicare?
Typically, you can get cheaper drugs through your Medicare plan by getting a prescription for a generic version. These tend to feature in lower formulary tiers, making them more affordable.
There's no generic version of Breztri, but other medications may be just as effective and more budget-friendly. Your Medicare plan may cover these.
In fact, since Breztri can be expensive, your plan might require prior authorization before they approve coverage. This could involve step therapy, where you're asked to try a different, equally effective but cheaper medication first.
In addition, AstraZeneca, the company that produces Breztri, offers a cost assistance program that may make this drug more affordable for Medicare enrollees. You'll need to visit the manufacturer's website to check your eligibility.
Takeaway
Breztri is a brand-name inhaler designed for long-term management of chronic obstructive pulmonary disease (COPD) in adults. Although Medicare drug plans may cover COPD inhalers like Breztri, coverage is not uniformly required. This means your coverage and cost depend on the specific medication and your specific plan.
Generally, Medicare Part D or a Medicare Advantage Prescription Drug (MAPD) plan provides drug coverage for Medicare, including for covered inhalers. However, if you need to use the drug with a nebulizer, your coverage would fall under Part B.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Plans unveiled for NHS funding to be linked to patient feedback
Plans unveiled for NHS funding to be linked to patient feedback

Yahoo

time30 minutes ago

  • Yahoo

Plans unveiled for NHS funding to be linked to patient feedback

NHS funding could be linked to patient feedback under new plans, with poorly performing services that "don't listen" penalised with less money. As part of the "10 Year Health Plan" to be unveiled next week, a new scheme will be trialled that will see patients asked to rate the service they received - and if they feel it should get a funding boost or not. It will be introduced first for services that have a track record of very poor performance and where there is evidence of patients "not being listened to", the government said. This will create a "powerful incentive for services to listen to feedback and improve patients' experience", it added. Sky News understands that it will not mean bonuses or pay increases for the best performing staff. NHS payment mechanisms will also be reformed to reward services that keep patients out of hospital as part of a new 'Year of Care Payments' initiative and the government's wider plan for change. Speaking to The Times, chief executive of the NHS Confederation Matthew Taylor expressed concerns about the trial. He told the newspaper: "Patient experience is determined by far more than their individual interaction with the clinician and so, unless this is very carefully designed and evaluated, there is a risk that providers could be penalised for more systemic issues, such as constraints around staffing or estates, that are beyond their immediate control to fix." He said that NHS leaders would be keen to "understand more about the proposal", because elements were "concerning". Read more from Sky News Health Secretary Wes Streeting said: "We will reward great patient care, so patient experience and clinical excellence are met with extra cash. These reforms are key to keeping people healthy and out of hospital, and to making the NHS sustainable for the long-term as part of the Plan for Change." In the raft of announcements in the 10 Year Health Plan, the government has said 201 bodies responsible for overseeing and running parts of the NHS in England will be scrapped. These include Healthwatch England, set up in 2012 to speak out on behalf of NHS and social care patients, the National Guardian's Office, created in 2015 to support NHS whistleblowers, and the Health Services Safety Investigations Body (HSSIB). Elsewhere, the new head of NHS England Sir Jim Mackey said key parts of the NHS appear "built to keep the public away because it's an inconvenience". "We've made it really hard, and we've probably all been on the end of it," he told the Daily Telegraph. "The ward clerk only works nine to five, or they're busy doing other stuff; the GP practice scrambles every morning."

Body fat predicts major health risk that BMI misses, researchers say
Body fat predicts major health risk that BMI misses, researchers say

Fox News

timean hour ago

  • Fox News

Body fat predicts major health risk that BMI misses, researchers say

Body mass index (BMI) may not be the most accurate predictor of death risk. A new study from the University of Florida found that BMI — a measurement that is commonly used to determine whether a person's weight is in a healthy range for their height — is "deeply flawed" in terms of predicting mortality. Instead, one's level of body fat is "far more accurate," concluded the study, which was published this week in the Annals of Family Medicine. To measure participants' body fat, the researchers used a method called bioelectrical impedance analysis (BIA), which uses a device to measure the resistance of body tissue to a small electrical current. Over a 15-year period, those who had high body fat were found to be 78% more likely to die than those who had healthy body fat levels, researchers found. They were also more than three times as likely to die of heart disease, the study noted. BMI — which is calculated by dividing weight by height, squared — was described as "entirely unreliable" in predicting the risk of death over a 15-year period from any cause. The study included 4,252 people in the U.S. and pulled data from the National Health and Nutrition Examination Survey. BMI should not be relied upon as a "vital sign" of health, according to senior author Frank Orlando, M.D., medical director of UF Health Family Medicine in Springhill. "I'm a family physician, and on a regular basis, we're faced with patients who have diabetes, heart disease, obesity and other conditions that are related to obesity," Orlando said in a press release for the study. "One of the routine measures we take alongside traditional vital signs is BMI. We use BMI to screen for a person having an issue with their body composition, but it's not as accurate for everyone as vital signs are," he added. BMI has been the international standard for measuring obesity since the 1980s, according to many sources, though some experts have questioned its validity. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." An individual is considered obese if their BMI is 30 or above, overweight if it is between 25 and 29.9, of "normal" weight in the range of 18.5 to 24.9, or underweight if lower than 18.5. While BMI is easy to calculate, one of its main limitations is that it cannot distinguish between muscle and fat mass, the researchers noted. "For example, people who are bodybuilders can really elevate their body mass index," Orlando said. "But they're healthy even with a BMI indicating that they're obese." "BMI is just so ingrained in how we think about body fat," Mainous added. "I think the study shows it's time to go to an alternative that is now proven to be far better at the job." Other methods, such as a DEXA (dual-energy X-ray absorptiometry) scan, may be even more accurate than BIA, but are much more expensive and not as accessible, the researchers noted. "If you talk to obesity researchers, they're going to say you have to use the DEXA scan because it's the most accurate," Mainous said in the release. "And that's probably true. But it's never going to be viable in a doctor's office or family practice." Dr. Stephen Vogel — a family medicine physician with PlushCare, a virtual health platform with primary care, therapy and weight management options — echoed the limitations of BMI. "It has been an easy measurement tool that helps us understand at-risk groups across various populations and demographics, but it doesn't provide accurate data from patient to patient," the North Carolina-based doctor, who was not involved in the study, told Fox News Digital. "These findings don't challenge the assumptions about BMI — they strengthen the message that new standards, delivered in a consistent and low-cost way, would provide better nuance for the individual when it comes to their overall physical health." "The main strengths of this study are a better correlation to an individual's risk of morbidity and mortality — however, the limitations lie in the fact that we don't have enough data to determine the right cutoff for these numbers, or to identify the right tools that will be both accurate and precise across the population," Vogel said. The researchers also acknowledged that body fat percentage thresholds haven't yet been as standardized as BMI and waist circumference. Also, the age range of the participants in the study was limited by the data source. "Future studies should extend this comparison of body fat to BMI in older adults," the researchers wrote. The study was also limited by focusing only on mortality as an outcome, they noted, without taking into account any developing diseases — such as heart failure or cancer — that could deepen the understanding of body fat as a risk factor. The goal, according to Vogel, is to have a cost-effective, consistent method that can be used across the population with reliable accuracy. "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all." "Benefits would come in the form of a more detailed list of information that helps providers and patients make informed decisions about the patient's health, which is ideal," Vogel noted. "I'm hopeful there's enough buzz around these measures that steps will continue to be taken toward regular implementation." For more Health articles, visit The researchers are hopeful that once standards are validated, measuring body fat percentage with bioelectrical impedance analysis could become standard of care. They added, "These data will drive better discussions in the doctor's office, as well as public health initiatives with the goal of improving the health of all."

Citi Expresses Optimism for Eli Lilly and Company (LLY)
Citi Expresses Optimism for Eli Lilly and Company (LLY)

Yahoo

timean hour ago

  • Yahoo

Citi Expresses Optimism for Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store